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SUMMARY
	 The	document	Medicines	Policy	2020	reports	on	the	joint	objectives	of	
the	social	welfare	and	healthcare	authorities	and	stakeholders	in	the	field	of	
medicines	by	the	year	2020.	
1. Pharmaceutical service is a part of the social welfare and healthcare 
service system 
Social	welfare	and	healthcare	services	must	be	increasingly	developed	to	
respond	to	the	needs	of	the	clients.	The	chief	objective	of	pharmaceutical	
service	 is	 to	 enable	 an	 efficient,	 safe,	 rational	 and	 cost-effective	
pharmacotherapy	for	all	those	in	need	of	it.	Interprofessional	cooperation	and	
agreeing	on	joint	policies	and	goals	regionally	and	locally	are	prerequisites	for	
securing	systematic	and	sustained	operations.	The	utilisation	of	information	
systems	available	in	social	welfare	and	healthcare	and	their	compatibility	
should	be	enhanced.	The	goal	is	to	deliver	all	prescriptions	electronically.	
2. Pharmaceutical service is of high quality, eff icient and cost- effective
A	good	availability	and	a	professionally	operating	distribution	of	medicinal	
products	must	be	secured	for	citizens	under	all	circumstances.	The	funding	
systems	must	underpin	such	pharmacotherapy	or	services	that	promote	the	
maintenance	of	the	population’s	working	and	functional	capacity	as	well	as	
independent	coping.	The	expenses	of	medicinal	products	must	be	evaluated	
as	a	part	of	the	total	healthcare	expenditures.	The	medicine	reimbursement	
system	must	 support	 cost-effective	 treatments	 in	 order	 to	 curb	 the	
expenditure.	The	know-how	and	practices	of	the	advisory	committees	on	
medicines,	hospital	pharmacies	and	medicine	dispensaries	in	establishing	a	
basic	formulary	of	medicinal	products,	in	purchases	of	medicinal	products	
and	competitive	tendering	needs	to	be	developed.	
3. Rational pharmacotherapy and good medication safety enhance the 
wellbeing of the population, improve public health and decrease the 
healthcare expenditures 
	The	clients’	own	role	and	responsibility	in	healthcare	and	medical	treatment	
should	be	increased	in	particular	in	the	treatment	of	long-term	diseases	and	
symptoms	that	they	can	easily	treat	themselves.	Successful	pharmacotherapy	
should	be	 improved	by	guidance	provided	for	 instance	by	pharmacists,	
dispensers	and	other	healthcare	professionals.	Treatments	following	the	
national	Current	Care	Guidelines	must	be	promoted.	The	access	of	healthcare	
professionals,	the	population	and	users	of	medicines	to	reliable	and	evidence-
based	information	on	medicinal	products	must	be	ensured.	The	consumers’	
and	patients’	critical	literacy	in	health	information	should	be	promoted.	
Key words: health care, health policy, health services, medicinal products, 
pharmaceutical service, pharmacotherapy, social services
4. Pharmaceutical research enhances health, wellbeing and employment 
Successful	 pharmaceutical	 research	 enhances	 the	 population’s	 health,	
wellbeing	and	employment,	and	therefore	innovations	and	their	utilisation	
in	the	field	of	medicines	ought	to	be	promoted.	The	assessment	of	the	
therapeutic	and	economic	value	of	medicinal	products	must	be	increased,	
and	optimally	uniform	methods	based	on	similar	criteria	and	evidence	should	
be	used	in	this	work.	The	methods	of	assessing	the	therapeutic	and	economic	
value	must	be	utilised	to	a	greater	extent	in	the	decision-making	concerning	
the	reimbursement	status	of	medicinal	products.	
5. Veterinary pharmaceutical service safeguards public health and 
promotes the wellbeing of people and animals 
An	appropriate	use	of	veterinary	medicinal	products	secures	the	safety	of	
consumers.	The	regional	and	national	access	to	veterinary	medicinal	products	
must	be	secured,	and	their	 imports	and	distribution	must	be	safe.	The	
monitoring	of	the	consumption	and	use	of	antimicrobial	agents	should	be	
developed,	and	adequate	systems	must	be	created	for	the	use,	dispensing	and	
prescribing	of	veterinary	medicinal	products.	
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Medicines	policy	is	a	part	of	the	social	welfare	and	health	policy.	The	present	
Medicines	Policy	2020	document	includes	the	medicines	policy	objectives	for	
the	coming	decade	and	sharpens	the	focus	of	the	social	welfare	and	healthcare	
strategy.
The	medicines	policy	outline	has	been	drawn	in	collaboration	with	the	
stakeholders	of	the	pharmaceutical	branch.	All	phases	of	the	medicine	life	
are	here	represented:	from	research	to	patients.
The	work	started	in	early	2010.	The	steering	and	preparatory	groups	as	
well	as	various	subgroups	elaborated	on	the	best	ways	to	provide	the	Finns	
with	necessary	pharmacotherapies,	also	in	the	future.	
The	process	towards	the	Medicines	Policy	2020	document	was	very	po-
sitive	and	successful.	Sitting	around	one	table,	the	participants	weighed	the	
strengths	and	weaknesses,	threats	and	possibilities	of	the	current	pharma-
ceutical	sector,	looking	for	means	to	further	improve	it.	In	addition	to	the	
joint	outlines,	we	learned	to	collaborate	in	a	more	efficient	way.
The	strategy	of	the	Ministry	of	Social	Affairs	and	Health	was	under	prepa-
ration	at	the	same	time.	According	to	the	new	strategy,	our	objective	is	a	so-
cially	sustainable	society	where	individuals	are	treated	equally,	ensuring	each	
and	everyone’s	inclusion	and	promoting	their	health	and	functional	capacity.	
The	medicines	policy	shares	these	objectives.	Successful	pharmacotherapy	
is	an	important	tool	in	the	treatment	of	diseases,	and	good	pharmaceutical	
services	must	be	equally	available	to	all.
Having	now	completed	the	Medicines	Policy	2020	document	we	are	happy	
to	continue	the	co-operation.	The	implementation	of	the	outlines	on	a	natio-
nal	and	international	level	will	call	for	good	interaction	and	open	communi-
cation	between	the	stakeholders	in	the	branch.	The	government	programme	
sets	the	framework	for	the	implementation	of	the	medicines	policy	but	the	
document	also	includes	several	objectives	specific	to	the	branch,	best	imple-
mented	in	day-to-day	practical	work.	Medicines	Policy	2020	is	a	positive	start	
to	a	sustainable	and	solid	practical	co-operation.
Kari	Välimäki	
Permanent	Secretary
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9FOREWORD
The	main	objective	of	the	pharmaceutical	service	is	to	provide	efficient,	safe,	
rational	and	cost-effective	pharmacotherapies	to	those	who	need	them.	The	
objective	can	be	reached	by	developing	the	current	system	towards	a	better	
match	with	the	customer	needs.	
Medicines	Policy	2020	is	a	document	reporting	on	the	joint	medicine	
policy	perspectives	of	the	social	welfare	and	healthcare	authorities	and	the	
branch	stakeholders	for	the	coming	decade.	The	policy	outlines	are	crystal-
lised	in	the	form	of	five	main	objectives:
The main medicines policy objectives for 2020 defined by the working group: 
1.	The	pharmaceutical	service	constitutes	a	part	of	the	social	welfare	and	
healthcare	service	system.	
2.	The	pharmaceutical	service	is	of	high	quality,	efficient	and	cost-effective.	
3.	Rational	pharmacotherapies	and	good	medication	safety	promote	people’s	
wellbeing	and	public	health,	decreasing	the	healthcare	expenditure.	
4.	Pharmaceutical	research	has	a	positive	impact	on	health,	wellbeing	and	
employment.	
5.	Veterinary	pharmaceutical	services	safeguard	public	health	and	promote	
the	wellbeing	of	humans	and	animals.	
The	Medicines	Policy	2020	document	presents	the	agreed	actions	for	the	
attainment	of	the	main	objectives	as	well	as	the	parties	that	are	responsible	
and	co-operate	for	their	implementation.	The	advantages	pursued	through	the	
actions	are	also	presented.	The	final	part	of	the	document	defines	a	follow-up	
plan	for	the	attainment	of	the	objectives	and	measurement	of	the	outcomes.	
The	Appendices	to	the	document	contain	numerical	data	about	the	phar-
maceutical	branch	as	well	as	definitions	of	terms	and	abbreviations	used	and	
the	co-operation	parties	involved.	
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1 PHARMACEUTICAL SERVICE 
CONSTITUTES PART OF SOCIAL 
WELFARE AND HEALTHCARE SERVICE 
SYSTEMS
Medicines	and	vaccines	play	an	essential	role	for	healthcare	and	medical	
care.	A	well	working	social	welfare	and	healthcare	service	system	benefits	
from	pharmaceutical	services,	and	vice	versa.	Well-functioning	services	and	
satisfied	customers	and	patients	are	shared	objectives.
The	core	values	of	medicines	policy	are	responsibility,	effectiveness,	quali-
ty,	equality	and	justice	as	well	as	economy	defined	as	cost-effectiveness.	The	
respect	of	human	dignity	and	customer-orientation	aim	at	the	promotion	of	
people’s	health	and	their	working	and	functional	capacity	under	all	circum-
stances.	Other	aims	include	sustainable	development,	transparent	systems	
and	systematic	operation	according	to	plan.
The	logistic	chain	in	the	pharmaceutical	services	includes	the	pharma-
ceutical	industry,	pharmaceutical	wholesalers,	outpatient	and	hospital	phar-
macies	and	medicine	dispensaries.	The	pharmaceutical	industry	is	in	charge	of	
pharmaceutical	research	and	development	as	well	as	production.	Universities,	
university	hospitals	and	various	research	institutes,	also	those	run	by	the	
authorities,	engage	in	research	focused	on	medicines	and	the	pharmaceuti-
cal	service.	The	pharmaceutical	industry	and	wholesalers	are	responsible	for	
pharmaceutical	imports	while	the	wholesalers	are	in	charge	of	the	stocking	
and	distribution	of	medicines.	The	retail	distribution	of	medicines	takes	pla-
ce	through	outpatient	and	hospital	pharmacies	and	medicine	dispensaries	
and,	to	a	limited	extent,	through	retail	grocery	trade	in	the	case	of	nicoti-
ne	replacement	therapy	products.	The	Institute	for	Health	and	Welfare		as	
well	as	hospital	pharmacies	and	medicine	dispensaries	are	in	charge	of	the	
distribution	of	vaccines	included	in	the	general	vaccination	programme.	The	
medicines	reimbursement	system	plays	a	central	role	for	the	operation	of	the	
pharmaceutical	service.	
The	provisions	related	to	medicines	and	vaccine	control	are	harmonised	
with	the	EU	regulations,	and	from	the	control	function	perspective,	Finland	
constitutes	a	part	of	the	control	network	of	the	EU	Member	States.	The	de-
cisions	influencing	the	Finnish	pharmaceutical	service	are	increasingly	made	
on	the	international	arenas.	The	EU	medicines	legislation	(Medicines	Direc-
tive1	and	Regulation2)	regulate	the	pharmaceutical	marketing	authorisations,	
distribution	and	control	at	the	community	level.	Pharmaceutical	distribution,	
medicine	reimbursement	systems	and	vaccine	programmes	fall	within	the	
national	competence.	The	main	provisions	on	the	pharmaceutical	service	are	
1  Directive 2001/83/EC of the European Parliament and of the Council 
2  Regulation (EC) No 726/2004 of the European Parliament and of the Council
11
included	in	the	Medicines	Act3	and	the	provisions	laid	down	on	the	basis	of	it,	
while	those	on	the	tasks	of	pharmaceutical	service	operators	are	included	in	
the	Act	on	Health	Care	Professionals.4	The	medicines	reimbursement	system	
is	defined	in	the	Health	Insurance	Act5.	The	Act	on	the	Status	and	Rights	
of	Patients6	contains	the	respective	healthcare-related	provisions	while	the	
ones	focusing	on	the	social	welfare	clients	are	contained	in	the	Act	on	the	
Status	and	Rights	of	Social	Welfare	Clients7.	There	is	also	specific	legislation	
on	medication	of	animals.
Administration and supervision of the social welfare and healthcare 
services 
The	Ministry	 of	 Social	 Affairs	 and	Health	 is	 responsible	 for	 the	
administrative	 development	 of	 the	 pharmaceutical	 service,	 the	
preparation	of	 the	medicines	 legislation	 and	 the	medicines	policy.	
The	Finnish	Medicines	Agency	Fimea	is	in	charge	of	the	authorisation	
and	control	functions	related	to	the	pharmaceutical	branch	as	well	as	
for	the	medicine	safety	issues.	Moreover,	Fimea	engages	in	research	
focusing	on	pharmaceutical-epidemiological,	medicines	policy	 and	
pharmacoeconomical	aspects,	forwarding	pharmaceutical	information	
to	 improve	 the	 effectiveness	 of	 the	 pharmaceutical	 service	 and	
pharmacotherapies.	The	Pharmaceuticals	Pricing	Board	is	the	responsible	
authority	for	the	decisions	on	medicine	prices	and	reimbursability.	The	
National	Supervisory	Authority	for	Welfare	and	Health	Valvira	guides	
and	supervises	the	operation	of	healthcare	organisations	and	professionals.	
It	also	covers	certain	functions	related	to	the	guidance	and	supervision	
of	social	welfare	services.	The	Social	Insurance	Institution	is	in	charge	of	
the	basic	social	security	of	the	residents	of	Finland,	including	medicine	
reimbursements.	Moreover,	 the	 Social	 Insurance	 Institution	 does	
research	focused	on	the	medicines	reimbursement	system	and	the	use	
of	medicines.	The	National	Institute	for	Health	and	Welfare	THL	is	an	
expert	institution	under	the	administration	of	the	Ministry	of	Social	
Affairs	and	Health.	The	Institute’s	responsibilities	include	the	vaccination	
programme.
3  Medicines Act 395/1987
4  Act on Health Care Professionals (559/1994)
5  Health Insurance Act 1224/2004
6  Act on the Status and Rights of Patients 785/1992
7  Act on the Status and Rights of Social Welfare Clients 812/2000
12
1.1 PHARMACEUTICAL SERVICE OPERATIONS ARE 
CUSTOMER-ORIENTED
The	pharmaceutical	service	must	be	developed	to	meet	the	customer	needs.	
Customer	orientation	also	means	that	the	patients	are	encouraged	to	take	
responsibility	for	their	own	care.	
The	nationally	agreed	care	recommendations,	such	as	the	Current	Care	
Guidelines,	promote	the	proper	use	of	medicines.	The	regional	agreement	
procedure	encompasses	the	municipal	healthcare	organisation	plans,	defined	
in	the	Health	Care	Act,	and	the	plans	are	based	on	the	regional	population’s	
health	follow-up	data	and	service	needs.	They	also	include	agreements	on	
municipal	co-operation,	objectives	and	responsible	bodies	for	the	promotion	
of	health	and	wellbeing	as	well	as	the	organisation	of	healthcare	services	
between	the	various	actors.	From	the	perspective	of	pharmaceutical	service,	
it	is	particularly	important	to	agree	on	the	local	practical	actions	to	promote	
co-operation.
Interprofessional	co-operation	between	various	healthcare	professionals	
lays	the	foundations	for	a	smooth	client-oriented	service	whole	that	transcends	
any	administrative	and	organisational	boundaries.	The	patients’	well-func-
tioning	care	pathways	and	successful	medication	can	be	promoted	through	
the	development	of	interprofessional	and	inter-organisational	co-operation	
models.
A	high	level	of	basic	training	of	the	healthcare	professionals	that	meets	the	
needs	of	practical	work	life	as	well	as	their	systematic	further	education	are	
tools	for	keeping	up	the	level	of	competence	needed	in	healthcare.	We	must	
ensure	that	the	level	of	professional	competence	remains	high	in	the	future.
Well-working	information	systems	–	including	the	e-prescription	–	will	
facilitate	the	effectiveness	and	overall	cost-effectiveness	analyses,	thereby	
improving	patient	safety.	Patient	records,	including	the	medication	data,	are	
already	now	mostly	in	digital	form.	However,	the	problems	in	the	transfer	of	
data	between	patient	record	systems	as	well	as	the	internal	usability	problems	
in	the	systems	weaken	their	feasibility	potential.	Compatible	information	
systems	would	support	the	continuity	of	care	and	comprehensive	monitoring	
of	its	outcomes.	As	a	consequence,	the	care	pathway	would	not	be	interrupted	
when	the	patient	moves	from	primary	healthcare	to	specialised	medical	care,	
or	a	social	welfare	client	moves	from	an	institution	to	the	non-institutional	
care	sector.	Comprehensive	recording	of	medication	data	is	a	prerequisite	for	
the	monitoring	of	care	outcomes	on	the	national,	regional	and	local	levels.
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Actions
1.	Develop	smooth,	client-oriented	and	cost-effective	operational	models	
in	social	welfare	and	healthcare	both	regionally	and	locally	in	view	of	
the	implementation	and	monitoring	of	pharmacotherapies.
	
Responsible	parties:	Ministry	of	Social	Affairs	and	Health,	National	
Institute	for	Health	and	Welfare
	
Co-operation	parties:	Fimea,	Valvira,	Social	 Insurance	 Institution,	
Regional	State	Administrative	Agencies,	professional	organisations,	
Finnish	Medical	Society	Duodecim,	municipalities,	hospital	districts,	
social	welfare	and	healthcare	units,	hospital	pharmacies,	medicine	
dispensaries,	pharmacies,	pharmaceutical	 industry,	pharmaceutical	
wholesalers.
2.	Agree	on	the	joint	pharmaceutical	service	objectives	to	ensure	systematic	
and	sustained	operations.
	
Responsible	parties:	Ministry	of	Social	Affairs	and	Health,	National	
Institute	 for	Health	and	Welfare,	Fimea,	Valvira,	Social	 Insurance	
Institution
	
Co-operation	parties:	All	pharmaceutical	branch	stakeholders
3.	Strengthen	interprofessional	operational	models	in	the	implementation	
of	the	patient’s	pharmacotherapy	and	consultation,	both	in	outpatient	
and	inpatient	care.
	
Responsible	parties:	Fimea,	National	Institute	for	Health	and	Welfare
	
Co-operation	parties:	Social	welfare	and	healthcare	units,	pharmacies,	
hospital	pharmacies,	medicine	dispensaries,	Association	of	Finnish	
Pharmacies,	University	Pharmacy,	professional	organisations,	universities
4.	Strengthen	co-operation	between	the	Ministry	of	Social	Affairs	and	
Health	on	the	one	hand	and	the	Ministry	of	Education	and	Culture	on	
the	other	hand	to	develop	basic,	continuing	and	on-site	education.	More	
efficient	co-operation	in	training	between	the	authorities	and	the	training	
units.
	
Responsible	parties:	Ministry	of	Social	Affairs	and	Health,	Ministry	of	
Education	and	Culture	
	
Co-operation	parties:	Fimea,	universities,	universities	of	applied	sciences,	
secondary	level	vocational	institutes
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5.	Develop	information	systems	used	in	social	welfare	and	healthcare,	related	
to	the	pharmaceutical	service,	improving	their	mutual	compatibility	and	
usability.
	
Responsible	parties:	Ministry	of	Social	Affairs	 and	Health,	Social	
Insurance	Institution	
	
Co-operation	parties:	Fimea,	National	Institute	for	Health	and	Welfare,	
hospital	districts,	information	system	providers
6.	Introduce	e-prescriptions,	with	the	aim	of	all	prescriptions	issued	in	
digital	form.
	
Responsible	parties:	Ministry	of	Social	Affairs	and	Health,	Fimea,	Social	
Insurance	Institution
	
Co-operation	parties:	Association	of	Finnish	Pharmacies,	University	
Pharmacy,	professional	organisations,	social	welfare	and	healthcare	units,	
pharmacies,	hospital	pharmacies,	medicine	dispensaries
Aims of actions:
	 improved	 operational	 models,	 planned	 action	 and	 improved	 co-
operation	makes	the	entire	healthcare	system	more	efficient	and	more	
client-oriented
	 the	pharmacotherapy	objectives	are	increasingly	attained
	 increased	 co-operation	 in	 the	 training	 of	 healthcare	 professionals	
improves	staff	competence
	 better	monitoring	of	treatments	improves	the	pharmacotherapy	outcomes
	 the	exchange	of	information	can	be	improved	through	well-functioning	
electronic	systems
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2 PHARMACEUTICAL SERVICE IS OF 
HIGH QUALITY, EFFICIENT AND COST-
EFFECTIVE
2.1 ENSURE ACCESS TO MEDICINES AND 
FUNCTIONING OF PHARMACEUTICAL SERVICE 
IN ALL CONDITIONS
The	access	 to	medicines	and	a	professionally	operating	pharmaceutical	
distribution	system	must	be	guaranteed	to	the	population.	The	medicines	
selection	must	ensure	the	rational	and	efficient	pharmacotherapy	of	patients.	
The	challenge	is	to	warrant	the	availability	of	novel	medicines	and	those	rarely	
needed	by	a	small	group	of	patients	as	well	as	to	guarantee	the	existence	of	
a	comprehensive	distribution	network	throughout	Finland,	the	remote	areas	
included.
The	access	to	and	availability	of	medicines	depends	on	the	functioning	of	
the	pharmaceutical	industry,	wholesalers,	pharmacies,	hospital	pharmacies	
and	medicine	dispensary	systems	as	well	as	on	the	predictability	of	the	factors	
influencing	the	pharmaceutical	market.		
From	the	perspective	of	the	current	distribution	system,	the	essential	
factors	influencing	the	access	to	medicines	include	the	comprehensiveness	of	
the	pharmacy	network	and	the	quality	of	its	operation	as	well	as	the	coverage	
and	delivery	times	of	the	wholesaler	operations.	The	pharmacies	must	also	
participate	in	the	monitoring	of	patient	care,	and	their	operations	will	be	inc-
reasingly	concentrated	on	health-promoting	pharmaceutical	service	functions.
Hospital	pharmacies	and	medicine	dispensaries	operate	as	a	part	of	the	
public	healthcare	system.	Cost-effectiveness	appraisals	must	be	performed	
as	an	integral	element	of	the	pharmaceutical	service.
Imported	medicines	play	an	important	role	in	pharmaceutical	service,	
and	therefore	the	access	to	medicines	under	emergency	circumstances	must	
be	ensured	through	the	obligatory	and	emergency	stockpiling	arrangements	
for	medicines	and	vaccines,	implemented	by	the	pharmaceutical	industry,	
hospitals,	healthcare	centres,	the	State,	the	National	Institute	for	Health	and	
Welfare	and	the	National	Emergency	Supply	Agency	as	well	as	by	maintaining	
the	conditions	for	national	pharmaceutical	production.
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Actions
1.	Develop	the	pharmaceutical	distribution	and	stockpiling	systems	to	
ensure	that	patients	have	rational,	safe	and	effective	pharmacotherapies	
on	a	nation-wide	scale.
	
Responsible	parties:	Ministry	of	Social	Affairs	and	Health,	Fimea
	
Co-operation	parties:	Association	of	Finnish	Pharmacies,	University	
Pharmacy,	 pharmaceutical	 wholesalers,	 pharmaceutical	 industry,	
pharmacies,	hospital	pharmacies,	medicine	dispensaries,	professional	
organisations
2.	Develop	the	obligatory	and	emergency	stockpiling	functions	in	a	cost-
effective	manner	to	guarantee	the	security	of	supply.
	
Responsible	parties:	Ministry	of	Social	Affairs	and	Health,	Fimea,	
National	Emergency	Supply	Agency
	
Co-operation	 parties:	National	 Institute	 for	Health	 and	Welfare,	
hospital	pharmacies,	medicine	dispensaries,	pharmaceutical	wholesalers,	
pharmaceutical	industry
3.	Enhance	the	competence	and	practices	of	pharmaceutical	advisory	
committees	and	hospital	pharmacies	and	medicine	dispensaries	 in	
relation	to	the	basic	medicine	formulary,	medicine	procurements	and	
competitive	bidding.
	
Responsible	 parties:	 Hospital	 districts,	 municipalities,	 hospital	
pharmacies,	pharmaceutical	industry
	
Co-operation	parties:	Ministry	of	Social	Affairs	and	Health,	Fimea
Aims of actions:
	 patients	receive	the	necessary	medication	under	all	circumstances
	 the	practices	of	outpatient	and	institutional	pharmaceutical	service	will	
improve	through	developed	processes
	 ensured	 competitive	 conditions	 will	maintain	 a	 well-functioning	
pharmaceutical	service
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2.2 FINANCING SYSTEMS PROMOTE 
MATERIALISATION OF ECONOMICALLY MOST 
ADVANTAGEOUS PHARMACOTHERAPIES AND 
EFFICIENT UTILISATION OF LIMITED RESOURCES
Financing	systems	also	influence	the	choice	of	pharmacotherapies.	Today,	
pharmacotherapies	are	mainly	funded	through	two	separate	channels.	The	
medicines	used	in	public	healthcare	are	included	in	the	treatment	costs	paid	
by	the	patient's	municipality	of	residence	or	the	joint	municipal	board.	The	
public	healthcare	sector	also	pays	for	the	vaccines	included	in	the	national	
vaccination	programme.	The	outpatient	medicines	prescribed	by	a	doctor	are	
partly	reimbursed	by	the	national	health	insurance	while	the	patients	pay	
the	whole	price	of	the	self-care	medicines	they	buy	without	a	prescription.	
The	current	two-tier	financing	system	may	in	some	cases	lead	to	partial	
optimisation	of	the	treatment.
The	financing	systems	must	support	pharmacotherapies	and	services	
which	promote	the	maintenance	of	working	and	functional	capacity	and	in-
dependent	coping	of	the	population.	The	financing	systems	must	be	evaluated	
and	developed	so	that	they	allow	for	a	rational	and	effective	pharmacotherapy	
for	the	patients.	It	is	indispensable	to	use	the	resources	efficiently	to	ensure	
the	availability	of	services	but	this	objective	must	not	constitute	any	risk	for	
patient	or	medicine	safety.
In	2008,	the	medicines	and	medicinal	consumer	goods	accounted	for	about	
14%	of	the	overall	healthcare	expenditure	(Appendix	2).	In	2009,	the	total	
sales	of	medicines	at	retail	prices,	taxes	included,	were	about	2.6	billion	euro,	
1.3%	less	than	in	2008	(Appendix	3).	The	health	insurance	reimbursements	
on	medicines	were	about	1.2	billion	euro	in	2009	(Appendix	3).	
Medicine	costs	must	be	seen	as	a	part	of	the	overall	healthcare	expendi-
ture.	According	to	the	report8	by	the	expert	group	at	the	National	Institute	
for	Health	and	Welfare	focusing	on	the	multi-tier	financing	of	social	welfare	
and	healthcare	services,	there	are	no	solid	arguments	to	separate	the	financing	
of	the	outpatient	medicines	from	the	rest	of	the	healthcare	system.	Medicine	
financing	responsibility	could	be	in	the	same	"basket"	with	the	other	forms	of	
treatment	and	operation	in	the	healthcare	system.	However,	in	the	context	
of	the	current	municipal	structure,	it	is	not	rational	to	decentralise	pharma-
cotherapy	financing	to	the	municipal	level.	Decentralisation	would	require	
considerably	stronger	organisations	to	shoulder	the	financing	responsibility.	
Any	possible	new	system	should	operate	on	the	basis	of	nationally	uniform	
medicine	reimbursement	criteria.	
8  Expert group of the National Institute for Health and Welfare: Sosiaali- ja terveydenhuollon monikanavaisen 
rahoituksen edut, haitat ja kehittämistarpeet, 17.11.2010
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Actions
1.	Consider	need	to	reform	the	financing	of	the	pharmaceutical	service	
(outpatient	and	institutional	care)	in	the	overall	context	of	the	social	
welfare	and	healthcare	reform.
	
Responsible	parties:	Ministry	of	Social	Affairs	and	Health,	National	
Institute	for	Health	and	Welfare
	
Co-operation	parties:	Fimea,	Social	 Insurance	Institution,	hospital	
districts,	municipalities,	pharmaceutical	industry
Aims of actions:
	 there	are	less	financing-related	problems,	such	as	partial	optimisation
	 medical	grounds	are	emphasised	in	the	choice	of	patients’	therapy	options
2.3 MEDICINE REIMBURSEMENT SYSTEM IS 
UNAMBIGUOUS AND DECISION-MAKING 
SYSTEM TRANSPARENT
The	core	objective	of	pharmaceutical	service	is	to	guarantee	high	quality,	
reasonable	prices	and	cost-effective	pharmacotherapies.	To	keep	costs	in	
control,	the	medicines	reimbursement	system	must	promote	cost-effective	
therapies.	The	share	of	patient	and	customer	co-payments	of	the	healthcare	
expenditure	must	remain	reasonable.
The	current	medicine	reimbursement	system	is	complicated	and	causes	
much	administrative	work.	The	future	individual	pharmacotherapies	will	
make	the	system	even	more	complex.	The	reimbursement	system	must	be	
simplified,	and	the	new	IT	possibilities	must	be	exploited	to	an	increasing	
extent.	The	implementation	of	the	system	must	be	in	proportion	to	the	tar-
gets	set	or	advantages	gained.
The	regulation	of	medicine	reimbursements	and	prices	is	extensively	used	
by	various	countries	as	one	means	of	controlling	the	medicine	expenditure.	
A	well-functioning	regulation	system	ensures	the	availability	of	reasonably-
priced	and	necessary	medicines,	and	supports	and	promotes	the	competition	
on	the	pharmaceutical	market.
Significant	cost	savings	are	generated	when	the	pharmaceutical	market	
competition	and	use	of	generics	are	promoted.	An	unambiguous	and	transpa-
rent	decision-making	system	helps	to	improve	the	functioning	of	the	reimbur-
sement	and	price	regulation	system.	The	openness	and	transparency	criteria	
apply	to	both	the	authorities	and	the	companies.
The	reference	price	system	has	been	an	efficient	means	to	curb	the	costs	
of	medicines	that	have	been	on	the	market	for	a	long	time	as	well	as	to	pro-
mote	price	competition.	The	system	must	be	further	developed,	taking	the	
experience	gained	by	various	stakeholders	and	patients	into	consideration.
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Actions
1.	Ensure	the	reasonableness	of	the	co-payment	burden	carried	by	the	
patients	in	need	of	medicines	through	a	joint	payment	ceiling	for	the	
social	welfare	and	healthcare	systems.
	
Responsible	parties:	Ministry	of	Social	Affairs	and	Health,	National	
Institute	for	Health	and	Welfare,	Social	Insurance	Institution
	
Co-operation	parties:	Municipalities
2.	Develop	the	decision-making	process	focusing	on	reimbursement	and	
price	regulation:
-	 by	implementing	an	electronic	application	procedure	and	utilising	
other	web-based	services
-	 by	analysing	the	need	for	new	operational	models	and	procedures	in	
price	regulation
-	 by	analysing	the	operational	models	and	evaluation	criteria	of	the	
pharmacotherapy	price	regulation,	in	use	for	a	long	time
	
Responsible	parties:	Ministry	of	Social	Affairs	and	Health
	
Co-operation	parties:	Fimea,	Social	Insurance	Institution,	pharmaceutical	
industry
3.	Examine	the	possibilities	to	decrease	the	administrative	work	caused	by	
the	medicines	reimbursement	system.
	
Responsible	parties:	Ministry	of	Social	Affairs	and	Health
	
Co-operation	parties:	Social	Insurance	Institution,	patient	organisations,	
pharmacies
4.	Develop	the	reference	price	system	on	the	basis	of	the	experiences	gained	
to	date.
	
Responsible	parties:	Ministry	of	Social	Affairs	and	Health
	
Co-operation	parties:	Fimea,	Social	Insurance	Institution,	pharmaceutical	
branch	stakeholders
Aims of actions:
	 the	processes	related	to	medicine	reimbursements	and	price	regulation	
improve
	 the	transparency	throughout	the	process	increases
	 developed	decision-making	processes	reduce	the	administrative	work
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3 RATIONAL PHARMACOTHERAPY 
AND GOOD MEDICATION SAFETY 
IMPROVE PEOPLE’S WELLBEING 
AND PUBLIC HEALTH, DECREASING 
HEALTHCARE EXPENDITURE
3.1 MEDICINE USERS ARE ENCOURAGED TO ASSUME 
RESPONSIBILITY FOR TREATMENT OF THEIR 
DISEASES
The	patients’	 and	customers’	 role	must	be	enhanced,	especially	 in	 the	
treatment	of	chronic	diseases	and	easily	manageable	symptoms.	The	patients	
or	their	representatives	must	be	involved	and	agree	on	the	objectives	and	
implementation	of	the	therapy.	The	task	of	pharmaceutical	service	is	to	
support	the	responsibility	and	involvement	of	the	medicine	user	 in	the	
pharmacotherapy.	Moreover,	the	advice	given	by	the	healthcare	professionals,	
pharmacists	and	dispensers	in	particular,	is	instrumental	for	the	proper	use	
of	self-care	medicines.	Promotion	of	health	and	prevention	of	diseases	are	
also	among	the	pharmaceutical	service	objectives.
Pharmacotherapies	do	not	always	materialise	as	instructed.	Irrational	or	
downright	erroneous	use	of	medicines	may	weaken	the	outcome	of	the	phar-
macotherapy,	cause	significant	adverse	health	effects	and	increase	the	use	and	
cost	of	healthcare	services.	The	attainment	of	pharmacotherapy	objectives	
can	be	promoted,	for	example,	by	using	tools	such	as	the	patient-specific	
medication	plans,	medicine	cards,	comprehensive	medication	reviews	(CMR)	
or	dose	dispensing.
Actions
1.	Support	the	patients	in	the	attainment	of	therapy	objectives.
	
Responsible	parties:	Social	welfare	and	healthcare	units,	pharmacies
	
Co-operation	parties:	Patients,	municipalities,	patient	organisations,	
Social	Insurance	Institution
2.	Promote	and	enhance	ways	to	improve	the	success	of	pharmacotherapies.
	
Responsible	parties:	Social	welfare	and	healthcare	units,	pharmacies,	
hospital	pharmacies,	patients
	
Co-operation	parties:	Municipalities,	professional	organisations,	Ministry	
of	Social	Affairs	and	Health,	Fimea,	National	Institute	for	Health	and	
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Welfare,	Valvira,	Social	Insurance	Institution,	patient	organisations,	
pharmaceutical	industry
3.	Promote	the	good	outcome	of	self-care	and	self-management	through	
the	advice	provided	by	pharmacists,	dispensers	and	other	healthcare	
professionals.	
	
Responsible	parties:	Association	of	Finnish	Pharmacies,	University	
Pharmacy,	pharmacies
	
Co-operation	parties:	Fimea,	professional	organisations
4.	Develop	ways	to	integrate	safe	self-care	into	the	healthcare	whole.
	
Responsible	parties:	Fimea,	National	Institute	for	Health	and	Welfare,	
Association	of	Finnish	Pharmacies,	University	Pharmacy,	pharmacies
	
Co-operation	 parties:	 Ministry	 of	 Social	 Affairs	 and	 Health,	
pharmaceutical	industry,	universities
Aims of actions:
	 the	patients’	treatment	adherence	improves
	 systematic	planning	improves	treatment	safety
3.2 INCREASE PRODUCTION OF RELIABLE 
INFORMATION ON RATIONAL 
PHARMACOTHERAPIES DISSEMINATED TO 
HEALTHCARE PROFESSIONALS AND MEDICINE 
USERS
Reliable	 and	 evidence-based	pharmaceutical	 information	 accessible	 to	
healthcare	professionals,	the	general	public	and	medicine	users	constitutes	the	
basis	for	the	rational	use	of	medicines.	For	healthcare	professionals,	the	most	
important	channels	of	information	on	pharmacotherapies	are	the	Current	
Care	guidelines	as	well	as	the	Terveysportti	database	and	related	specialised	
databases,	such	as	the	ones	on	medicine	interactions	and	prices.
The	general	public	and	the	medicine	users	obtain	pharmaceutical	informa-
tion	from	different	sources.	Abundant	pharmaceutical	information	is	available	
in	the	Internet	but	the	quality	of	the	information	varies.	The	organisation	of	
pharmaceutical	information	in	the	web-based	pharmacy	operations	is	a	new	
challenge.	We	must	also	remember	that	not	everybody	uses	computers	or	
other	means	of	ITC.
Proper	advice	on	the	use	of	medicines	is	particularly	necessary	to	the	
patients	with	long-term	pharmacotherapies.	There	is	insufficient	reliable	
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pharmaceutical	information,	with	a	balanced	presentation	of	the	medicine	
efficacy	and	safety	vis-à-vis	other	available	therapy	options.	The	threats	in-
clude	the	unnecessary	increase	in	medicine	use,	improper	use	of	the	medi-
cines	and	medicalisation.
Actions
1.	Strengthen	basic,	further	and	continuing	education	on	pharmacotherapies,	
information	 sources	 and	 patient	 advice	 functions	 targeted	 at	
pharmaceutical	and	healthcare	professionals.
	
Responsible	parties:	Ministry	of	Education	and	Culture,	universities,	
universities	of	applied	sciences,	social	welfare	and	healthcare	units,	
training	organisations,	secondary	level	vocational	institutions
	
Co-operation	parties:	Ministry	of	Social	Affairs	and	Health,	Fimea,	
professional	organisations,	pharmacies,	hospital	pharmacies,	medicine	
dispensaries,	professional	organisations
2.	Support	measures	to	provide	social	welfare,	healthcare	and	pharmaceutical	
points	of	operation	and	those	involved	in	the	practical	pharmacotherapy	of	
patients	with	proper,	necessary	and	updated	pharmaceutical	information	
sources	and	to	ensure	that	there	is	competence	to	use	these	sources.
	
Responsible	parties:	Social	welfare	and	healthcare	units,		Association	
of	Finnish	Pharmacies,	University	Pharmacy,	Duodecim,	pharmacies,	
hospital	pharmacies,	medicine	dispensaries
	
Co-operation	parties:	Ministry	of	Social	Affairs	and	Health,	Fimea,	
National	Institute	for	Health	and	Welfare,	Social	Insurance	Institution,	
universities,	universities	of	applied	sciences,	professional	organisations,	
secondary	level	vocational	institutes
3.	Ensure	that	healthcare	professionals,	the	general	public	and	medicine	
users	 have	 access	 to	 reliable	 and	 evidence-based	 pharmaceutical	
information.
	
Responsible	party:	Fimea
	
Co-operation	parties:	Ministry	of	Social	Affairs	and	Health,	National	
Institute	for	Health	and	Welfare,	Social	Insurance	Institution,	universities,	
universities	of	applied	sciences,		Association	of	Finnish	Pharmacies,	
University	Pharmacy,	social	welfare	and	healthcare	units,	pharmacies,	
hospital	pharmacies,	medicine	dispensaries,	Duodecim,	professional	
organisations,	secondary	level	vocational	institutions,	pharmaceutical	
industry,	patient	organisations
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4.	Strengthen	national	and	international	research	and	development	geared	
towards	the	production	of	pharmaceutical	information	and	services,	
including	their	effectiveness	analyses.
	
Responsible	parties:	Fimea,	universities,	universities	of	applied	sciences	
	
Co-operation	parties:	Ministry	of	Social	Affairs	and	Health,	National	
Institute	for	Health	and	Welfare,	Social	Insurance	Institution
5.	Promote	health	information	literacy	and	critical	analysis	skills	among	
consumers	and	patients.
	
Responsible	parties:	Universities,	 schools,	 adult	education	centres,	
pharmacies
	
Co-operation	parties:	Fimea,	social	welfare	and	healthcare	units
Aims of actions:
	 healthcare	professionals	and	medicine	users	have	better	information	on	
medicinal	products	and	their	use
	 high-quality	and	updated	pharmaceutical	information	may	decrease	the	
number	of	adverse	interactions	of	medicines	used	by	a	patient
	 co-operation	promotes	the	R&D	on	medicines,	and	the	research	outcome	
can	be	used	to	improve	the	quality	and	effectiveness	of	pharmaceutical	
services
	 consumers	and	patients	are	more	competent	in	assessing	the	quality	of	
the	information	obtained
3.3 PROMOTE EFFICIENT, SAFE, RATIONAL AND 
COST-EFFECTIVE USE AND PRESCRIPTION OF 
MEDICINES
In	addition	to	the	prescription	of	medicines,	the	other	factors	influencing	
the	appropriateness	of	pharmacotherapies	include	the	regular	recording	and	
assessment	of	therapy	outcomes	and	adverse	effects,	as	well	as	the	transfer	
of	the	information	between	the	healthcare	units	participating	in	the	care	of	
the	patient.	Pharmacotherapies	should	not	be	unnecessarily	used	instead	of	
non-medicinal	forms	of	therapy,	such	as	healthy	habits	and	life	changes.
The	training	for	a	rational	prescription	practice,	already	started	during	
medical	and	pharmaceutical	studies,	should	be	further	developed.	The	ob-
jective	is	to	apply	electronic	tools	and	operational	models	in	medicine	presc-
riptions,	shown	to	be	useful	and	cost-effective	in	practical	work	or	through	
other	evidence-based	means.	
24
In	particular,	the	patients	with	several	simultaneous	medicines,	older	
persons	and	other	special	groups	should	have	medication	plans	and	their	
pharmacotherapies	and	their	needs	should	be	assessed	on	a	regular	basis.	The	
systems	supporting	rational	prescription	practices	should	be	further	develo-
ped	and	introduced.
Actions
1.	Consider	pharmacotherapies	as	an	element	of	the	patient's	comprehensive	
care,	remembering	the	appropriate	preventive	medications	and	non-
medicinal	forms	of	therapy.
	
Responsible	parties:	Social	welfare	and	healthcare	units,	pharmacies
	
Co-operation	parties:	Social	Insurance	Institution,		Association	of	Finnish	
Pharmacies,	University	Pharmacy,	professional	organisations
2.	Promote	comparative	evaluations	and	financing	of	pharmacotherapies	
and	non-medicinal	forms	of	therapy.
	
Responsible	parties:	Ministry	of	Social	Affairs	and	Health,	Fimea,	
universities,	National	Institute	for	Health	and	Welfare,	Social	Insurance	
Institution
	
Co-operation	 parties:	 Social	welfare	 and	 healthcare	 units,	 Social	
Insurance	Institution,	pharmaceutical	industry,	research	funding	parties
3.	Promote	therapies	complying	with	the	national	Current	Care	guidelines	
and	guarantee	the	resources	for	the	development	and	maintenance	of	the	
support	systems.
	
Responsible	parties:	Ministry	of	Social	Affairs	and	Health,	Fimea,	
National	Institute	for	Health	and	Welfare,	Social	Insurance	Institution,	
Duodecim,	healthcare	units,	pharmacies,	hospital	pharmacies
	
Co-operation	parties:	Professional	organisations
4.	Draft	 instructions	 on	 the	 contents	 and	 needs	 of	 comprehensive	
medication	reviews	(CMRs),	defining	the	tasks	of	various	professional	
groups	in	this	process.
	
Responsible	parties:	Fimea,	National	Institute	for	Health	and	Welfare
	
Co-operation	parties:	Duodecim,	professional	organisations,	universities
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5.	Enhance	the	quality	of	pharmacotherapies	by	increasing	the	expertise	in	
clinical	pharmacology	and	ward-based	pharmacy	activities	in	hospitals,	
and	by	utilising	unit-specific	pharmacotherapy	plans.	
	
Responsible	parties:	Healthcare	units,	hospital	pharmacies,	universities
Aims of actions:
	 increase	in	therapy	effectiveness,	decrease	in	the	number	of	adverse	
reactions	caused	by	medicines	and	improved	therapy	outcomes
	 rational	pharmacotherapy	brings	cost	savings	by	decreasing	the	need	of	
health	services	and	unnecessary	use	of	medicines
3.4 IMPROVED MEDICATION SAFETY PROMOTES 
PUBLIC HEALTH
Marketing	authorisation	practices	and	subsequent	supervision	are	central	tools	
to	ensure	drug	safety.	These	processes	have	been	harmonised	in	the	European	
Union.	In	Finland,	Fimea	is	responsible	for	this	area.
The	Finnish	system	works	well	as	concerns	notifications	of	product	defects	
and	subsequent	reactive	steps.	The	dissemination	of	counterfeit	medicines	
through	international	Internet-based	trade	and	illegal	importation	constitute	
new	threats	in	this	respect.
Medication	safety	refers	to	the	safety	in	relation	to	the	use	of	medici-
nes.	The	term	covers	the	principles	and	operations	of	the	social	welfare	and	
healthcare	units,	geared	at	ensuring	the	safety	of	pharmacotherapies	and	
protecting	the	patient	from	harm.	Medication	safety	is	threatened	by	factors	
such	as	minimal	participation	by	the	patients	in	their	own	care	and	lack	of	
pharmacotherapy	coordination.	Pharmacotherapy	plans	made	at	points	of	
care,	reports	on	dangerous	and	adverse	effects	as	well	as	security-enhancing	
databases	can	promote	medication	safety.
Actions
1.	Strengthen	and	develop	co-operation	in	the	supervision,	monitoring	and	
guidance	of	drug	safety	and	medication	safety	issues.
	
Responsible	parties:	Ministry	of	Social	Affairs	and	Health,	National	
Institute	for	Health	and	Welfare,	Fimea,	Valvira
	
Co-operation	parties:	Social	welfare	and	healthcare	units,	pharmacies,	
hospital	pharmacies,	medicine	dispensaries,	professional	organisations,	
universities,	pharmaceutical	industry,	pharmaceutical	wholesalers
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2.	Intensify	national	and	international	co-operation	between	the	authorities	
to	recognise	counterfeit	medicines	and	solve	related	crime
	
Responsible	parties:	Fimea,	Valvira,	Customs,	Police,	pharmaceutical	
industry
	
Co-operation	parties:	Ministry	of	Social	Affairs	and	Health,	Social	
Insurance	Institution
3.	Increase	the	general	public’s	awareness	of	counterfeit	medicines	and	risks	
related	to	medicines	acquired	through	the	Internet.
	
Responsible	parties:	Fimea,	National	Institute	for	Health	and	Welfare,	
pharmaceutical	industry,	pharmacies,	hospital	pharmacies
	
Co-operation	parties:	Ministry	of	Social	Affairs	and	Health,	healthcare	
units,	professional	organisations,	pharmaceutical	wholesalers,	patient	
organisations
4.	Enhance	medication	safety	research	to	recognise	risk	medicines	and	
processes,	also	using	the	related	registers.
	
Co-operation	parties:	Fimea,	National	Institute	for	Health	and	Welfare,	
Social	Insurance	Institution,	universities,	university	hospitals
Aims of actions:
	 good	drug	safety	and	medication	safety
	 improved	public	awareness	of	counterfeit	medicines
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4 PHARMACEUTICAL RESEARCH 
IMPROVES HEALTH, WELLBEING AND 
EMPLOYMENT RATES
4.1 PROMOTE GENERATION AND EXPLOITATION 
OF PHARMACEUTICAL INNOVATIONS 
Finland	is	the	venue	of	high-quality	biomedical	and	clinical	research,	and	we	
have	sufficient	competence	in	industrial	pharmaceutical	development	and	
thus	the	conditions	to	generate	new	pharmaceutical	innovations.
The	areas	requiring	development	include	the	healthcare	permit	processes	
and	contractual	negotiations	related	to	research	as	well	as	the	opportunities	
granted	to	researchers	to	participate	in	pharmaceutical	development	work.	
Enhanced	exploitation	of	the	outcomes	obtained	in	basic	research	would	
improve	patentability	opportunities	and	thus	also	the	exploitation	of	phar-
maceutical	innovations.	More	comprehensive	and	more	sustained	pharma-
ceutical	risk	funding	would	promote	business	opportunities.	Pharmaceutical	
development	creates	new	jobs	not	only	in	the	pharmaceutical	companies	but	
also	in	related	service	companies	and	in	the	healthcare	sector.	
Pharmaceutical	development	calls	for	active	national	and	international	
co-operation	and	networking	among	the	experts	of	various	disciplines	as	
well	as	among	the	various	pharmaceutical	stakeholders.	We	should	anticipate	
the	changes	in	healthcare	resulting	from	pharmaceutical	development.	The	
participation	in	the	pharmaceutical	development	on	the	EU	level	will	provide	
the	research	institutes	and	companies	excellent	opportunities	to	this	antici-
patory	work	and	international	networking.	For	the	pharmaceutical	branch,	
it	is	important	that	Finland	is	involved	and	influencing	the	EU	medicines	
policy	and	legislation.
Actions
1.	Strengthen	the	co-operation	between	basic	research	and	clinical	trials	
of	medicines.
	
Co-operation	parties:	Ministry	of	Social	Affairs	and	Health,	Ministry	of	
Education	and	Culture,	Fimea,	National	Institute	for	Health	and	Welfare,	
National	Committee	on	Medical	Research	Ethics	TUKIJA,	universities,	
universities	of	applies	sciences,	healthcare	units,	Academy	of	Finland,	
university	hospitals,	pharmaceutical	industry,	professional	organisations
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2.	Provide	healthcare	professionals	with	better	opportunities	to	engage	in	
clinical	trials	of	medicines.
	
Co-operation	parties:	Ministry	of	Social	Affairs	and	Health,	Ministry	of	
Education	and	Culture,	Fimea,	National	Institute	for	Health	and	Welfare,	
universities,	universities	of	applies	sciences,	healthcare	units,	Academy	
of	Finland,	university	hospitals
3.	Simplify	the	administrative	processes	related	to	contracts	and	permits	
related	to	pharmaceutical	research	and,	if	necessary,	revise	the	respective	
legislation.
	
Responsible	party:	Ministry	of	Social	Affairs	and	Health
	
Co-operation	parties:	Fimea,	National	Institute	for	Health	and	Welfare,	
Valvira,	National	Committee	on	Medical	Research	Ethics	TUKIJA
4.	The	Ministry	of	Social	Affairs	 and	Health	will	work	 in	closer	 co-
operation	with	the	Ministry	of	Education	and	Culture	and	the	Ministry	
of	Employment	and	the	Economy	to	develop	the	research	operations.
	
Responsible	parties:	Ministry	of	Social	Affairs	and	Health,	Ministry	of	
Education	and	Culture,	Ministry	of	Employment	and	the	Economy
	
Co-operation	parties:	universities
5.	Promote	national	and	international	co-operation	and	networking	in	
pharmaceutical	research	and	development	among	hospital	districts,	
research	schools,	universities,	companies	and	authorities.	
	
Responsible	parties:	Fimea,	Finnish	Funding	Agency	for	Technology	and	
Innovation	TEKES
	
Co-operation	parties:	Ministry	of	Social	Affairs	and	Health,	Ministry	
of	Employment	and	the	Economy,	National	Institute	for	Health	and	
Welfare,	universities,	universities	of	applies	sciences,	Finnish	Innovation	
Fund	SITRA,	pharmaceutical	industry,	Academy	of	Finland,	hospital	
districts,	professional	organisation
Aims of actions:
	 more	pharmaceutical	research	is	done	and	the	related	practices	become	
less	complicated
	 new	jobs	in	this	sector	are	generated	in	Finland
	 in	the	long	run,	the	number	of	Finnish	pharmaceutical	innovations	may	
grow
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4.2 PROMOTE RATIONAL PHARMACOTHERAPIES 
THROUGH EVALUATIONS OF THERAPEUTIC 
AND ECONOMIC VALUE OF MEDICINES
The	information	on	the	therapeutic	and	economic	value	of	medicines	and	
vaccines,	in	other	words,	their	cost-effectiveness,	is	the	foundation	for	their	
rational	use.	To	become	reimbursable,	novel	medicines	must	be	accompanied	
with	a	health	economic	evaluation.	Health	economic	studies	are	usually	
performed	at	the	early	stages	of	medicine	development.	At	that	point,	there	is	
not	yet	any	experience	on	the	impacts	of	the	medicine	on	the	population	level.
Today,	the	requirements	and	resources	for	cost-effectiveness	appraisals	of	
outpatient	medicines	on	the	one	hand	and	the	hospital	medicines	on	the	other	
hand	are	different.	The	Pharmaceuticals	Pricing	Board	has	been	appraising	
reimbursable	outpatient	medicines	since	1998,	while	the	limited	resources	
available	to	hospitals	have	been	allocated	to	uses	other	than	the	medications	
assessments.	In	both	sectors,	the	limited	number	of	experts	and	the	lack	of	
effectiveness	data	influence	the	development	of	evaluations	and	the	possibility	
to	estimate	the	respective	costs.	To	accumulate	versatile	and	updated	research	
and	evaluation	data	on	medicines,	it	is	indispensable	that	researchers	have	
access	to	registers	containing	the	information	on	all	prescribed	and	dispensed	
medicines	as	well	as	on	the	integrated	care	pathways	and	therapy	outcomes.
More	cooperation	between	the	organisations	and	researchers	in	the	sector	
is	needed	to	develop	the	operations.	According	to	the	respective	legislation,	
the	Fimea	responsibilities	include	both	the	pharmacoeconomic	research	and	
the	cost-effectiveness	evaluations,	in	other	words,	the	evaluations	of	the	the-
rapeutic	and	economic	value	of	pharmacotherapies.	Moreover,	Fimea	should	
build	up	cooperation	in	these	sectors.	At	the	request	of	the	Pharmaceuticals	
Pricing	Board,	Fimea	can	also	perform	evaluations	related	to	the	medicine	
reimbursement	and	price	decisions.
Actions
1.	Promote	the	training	of	experts	in	pharmaceutical	epidemiology	and	
health	economics	in	collaboration	with	the	authorities,	universities	and	
other	educational	institutions.	
	
Responsible	parties:	Ministry	of	Education	and	Culture,	universities,	
universities	of	applied	sciences
	
Co-operation	parties:	Ministry	of	Social	Affairs	and	Health,	Fimea,	
Ministry	of	Employment	and	the	Economy,	National	Institute	for	Health	
and	Welfare
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2.	Ensure	that	the	evaluations	on	the	therapeutic	and	economic	value	of	
medicines	are	performed	using	uniform,	evidence-based	procedures	
based	on	as	equal	criteria	as	possible.	
	
Responsible	parties:	Fimea,	Social	Insurance	Institution
	
Co-operation	parties:	Ministry	of	Social	Affairs	and	Health,	National	
Institute	for	Health	and	Welfare,	Duodecim,	pharmaceutical	industry
3.	Increase	national	and	international	co-operation	in	the	cost-effective	
evaluations	of	medicines.
	
Responsible	parties:	Fimea,	Social	Insurance	Institution
	
Co-operation	parties:	Ministry	of	Social	Affairs	and	Health,	National	
Institute	for	Health	and	Welfare,	pharmaceutical	industry,	universities
4.	Make	increased	use	of	evaluations	of	the	therapeutic	and	economic	
value	of	medicines	in	the	decision-making	related	to	the	reimbursement	
status	of	a	medicinal	product.	Promote	the	use	of	evaluation	data	in	all	
medicine-related	decision-making.
	
Responsible	parties:	Ministry	of	Social	Affairs	and	Health,	Fimea,	
National	Institute	for	Health	and	Welfare,	Social	Insurance	Institution
	
Co-operation	parties:	pharmaceutical	industry
5.	Create	 a	 comprehensive	 prescription	 database,	 accumulating	 the	
information	on	all	dispensed	prescription-only	medicines.	Make	sure	
that	the	social	welfare	and	healthcare	registers	can	be	utilised	in	the	
research	on	medicines.
	
Responsible	parties:	Fimea
	
Co-operation	parties:	Social	Insurance	Institution,	pharmacies,	hospital	
districts,	hospital	pharmacies,	medicine	dispensaries
Aims of actions:
	 information	on	cost-effectiveness	helps	to	allocate	the	resources	to	
rational	therapies
	 improved	national	and	international	co-operation	improves	evaluation	
processes	and	promotes	the	exchange	of	information
	 increased	 information	on	medicine	use	helps	 to	 identify	 the	areas	
requiring	new	resources
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5 VETERINARY SERVICE SAFEGUARDS 
PUBLIC HEALTH AND PROMOTES 
WELLBEING OF HUMANS AND 
ANIMALS
5.1 RATIONAL USE OF VETERINARY MEDICINES 
GUARANTEES CONSUMER SAFETY
The	use	of	veterinary	medicines	must	be	rational	to	ensure	public	health	
and	consumer	safety.	Controlled	use	of	antimicrobial	medicines	requires	
particular	attention.	Animal	wellbeing	will	influence	the	quality	of	animal-
based	 foodstuffs,	 the	 cost-effectiveness	 of	 animal	 production	 and	 the	
wellbeing	of	humans.
The	regional	and	national	availability	of	veterinary	medicines	must	be	
ensured,	and	their	imports	and	distribution	must	be	safe.	The	Finnish	vete-
rinary	medicine	market	is	small,	and	therefore	the	number	and	selection	of	
medicines	with	marketing	authorisations	are	not	sufficient	to	cover	all	indica-
tions.	The	availability	of	several	veterinary	medicines	and	vaccines	is	ensured	
through	special	permits.	Difficulties	in	the	access	to	vaccines	may	lead	to	the	
spreading	of	animal	diseases.	In	case	of	production	disturbances,	the	small	
selection	of	generic	medicines	may	have	a	significant	negative	impact	on	the	
availability	of	the	medicines.	The	consequences	would	include	considerable	
problems	in	animal	wellbeing,	not	to	mention	economic	losses.
The	medication	of	production	animals	must	always	take	place	with	due	
attention	to	food	safety.	The	safety	of	pharmaceutical	residues	has	been	eva-
luated,	and	the	medicines	have	appropriate	safety	periods	which	must	be	
followed.	A	national	monitoring	programme	follows	pharmaceutical	residues	
in	foodstuffs	comprehensively	and	systematically.	
Contrary	to	many	European	countries,	Finland	is	free	from	many	com-
mon	animal	diseases,	and	we	must	maintain	this	situation.	The	inspection	
of	imported	vaccine	batches	and	their	high	quality	ensure	that	pathogenic	
substances	do	not	spread	in	the	country	in	the	form	of	vaccine	impurities.	If	
vaccines	are	not	available,	we	risk	having	serious	animal	disease	epidemics	that	
may	also	lead	to	lower	productivity.	Some	vaccines	also	provide	the	animals	
with	protection	against	zoonotic	pathogens	that	may	be	dangerous	to	humans.	
The	use	of	veterinary	medicines	must	be	based	on	reliable	information.	
The	production	and	dissemination	of	reliable	and	evidence-based	informa-
tion	on	veterinary	medicines	will	promote	the	correct	and	safe	use	of	the	
medicines	in	question.	
32
Actions
1.	Promote	 animal	 health	 and	 wellbeing	 through	 better	 veterinary	
healthcare	and	medicine,	improved	living	conditions	of	animals	and	more	
active	controls.	Emphasise	preventive	animal	healthcare	instead	of	mere	
treatment	of	diseases.
	
Responsible	parties:	Ministry	of	Agriculture	and	Forestry,	Evira
	
Co-operation	parties:	Fimea,	Ministry	of	Social	Affairs	and	Health,	
universities,	food	industry
2.	Improve	nation-wide	availability	of	veterinary	medicines	and	their	
sufficiently	comprehensive	selection.	Ensure	the	availability	of	animal	
vaccines	during	epidemics.
	
Responsible	parties:	Fimea,	Ministry	of	Social	Affairs	and	Health,	
pharmaceutical	industry,	pharmaceutical	wholesalers,	pharmacies
	
Co-operation	parties:	Ministry	of	Agriculture	and	Forestry,	Evira,	
universities
3.	Communicate	actively	on	the	appropriate	use	of	veterinary	medicines	
through	channels	close	to	the	users.	Information	on	the	risks	of	illegal	
importation	and	Internet	trade.
	
Responsible	parties:	Fimea,	Evira
	
Co-operation	parties:	Ministry	of	Agriculture	and	Forestry,	universities,	
professional	organisations,	pharmacies,	pharmaceutical	industry
4.	Develop	monitoring	systems	focusing	on	the	consumption	and	use	of	
antimicrobials	used	on	animals,	creating	sufficient	systems	to	accumulate	
information	on	 the	use,	 dispensing	 and	prescription	of	 veterinary	
medicines	for	different	indications,	broken	down	by	animal	species.	
Promoted	compliance	with	antimicrobial	recommendations.
	
Responsible	parties:	Fimea,	Ministry	of	Agriculture	and	Forestry,	Evira
	
Co-operation	parties:	Ministry	of	Social	Affairs	and	Health,	universities,	
professional	organisations,	pharmacies,	pharmaceutical	industry
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5.	Promote	 sensitivity	monitoring	of	microbes	 isolated	 from	animals,	
launching	permanent	publications	that	report	on	the	antimicrobial	
resistance	situation	related	to	both	human	and	animal	medicine.
	
Responsible	parties:	Evira,	National	Institute	for	Health	and	Welfare,	
Ministry	of	Agriculture	and	Forestry
	
Co-operation	parties:	Fimea,	Ministry	of	Social	Affairs	and	Health,	
universities
6.	Promote	co-operation	between	pharmaceutical	experts	and	enhance	
animal	medication	contents	in	the	basic	education	of	various	professional	
groups.
	
Responsible	parties:	Ministry	of	Agriculture	and	Forestry,	Fimea,	Evira
	
Co-operation	parties:	Ministry	of	Social	Affairs	and	Health,	universities,	
professional	organisations
7.	Draft	a	national	strategy	for	producing	reliable	and	understandable	
veterinary	medicine	information.
	
Responsible	parties:	Fimea,	Ministry	of	Social	Affairs	and	Health
	
Co-operation	parties:	Fimea,	Ministry	of	Social	Affairs	and	Health,	
Ministry	of	Agriculture	and	Forestry,	Evira,	universities,	professional	
organisations,	pharmaceutical	industry
Aims of actions:
	 the	access	to	veterinary	medicines	improves	and	their	use	becomes	
increasingly	rational
	 food	safety	remains	at	a	good	level
	 the	use	of	antimicrobials	is	more	appropriate
	 information	on	the	proper	use	of	veterinary	medicines	is	more	accessible	
to	the	authorities	and	medicine	users
	 the	development	of	preventive	healthcare	of	productive	animals	enhances	
the	profitability	of	agriculture
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6 FOLLOW-UP PLAN FOCUSING ON 
IMPLEMENTATION OF PROPOSED 
MEDICINES POLICY 2020 ACTIONS
The	Medicines	Policy	document	outlines	the	respective	decision-making	
until	the	year	2020.	The	Ministry	of	Social	Affairs	and	Health	will	lead	the	
work	for	the	attainment	of	medicines	policy	objectives.	The	strategic	steering	
takes	place	through	the	performance	agreements	between	the	Ministry	
and	the	agencies	under	its	umbrella.	However,	to	reach	the	objectives,	all	
pharmaceutical	branch	stakeholders	need	to	collaborate.
6.1 PRACTICAL ACTIONS AND EVALUATION OF 
IMPACTS
The	definition	of	the	practical	actions	under	the	medicines	policy	outlines	
and	the	respective	evaluation	are	continuous	processes.	This	work	takes	place	
in	collaboration	with	the	stakeholders	in	the	pharmaceutical	branch.
The	objectives	and	the	need	for	measures	will	be	revised	at	regular	inter-
vals.	Two	monitoring	groups	will	be	established	for	the	purpose:
a)	Medicines	Group	constituted	by	the	pharmaceutical	authorities	(Ministry	
of	Social	Affairs	and	Health,	Fimea,	Social	Insurance	Institution,	National	
Institute	for	Health	and	Welfare,	Valvira,	Finnish	Food	Safety	Authority	
Evira,	and	Ministry	of	Agriculture	and	Forestry),	meeting	once	a	year.	
b)	Pharmaceutical	 Forum	 constituted	 by	 the	 pharmaceutical	 branch	
stakeholders,	meeting	every	two	years.
The	Ministry	of	Social	Affairs	and	Health	will	convene	the	monitoring	
groups.	Using	specifically	developed	indicators,	the	Finnish	Medicines	Agency	
FIMEA	and,	if	necessary,	the	other	agencies	will	gather	information	on	the	
success	of	the	medicines	policy	actions	and	attainment	of	objectives	for	the	
monitoring	groups.	
The	impacts	of	the	actions	can	be	evaluated	from	many	perspectives,	inclu-
ding	that	of	the	individual	patient,	society	or	the	pharmaceutical	branch	sta-
keholders.	The	Medicines	Policy	2020	document	lists	the	advantages	that	the	
actions	are	expected	to	generate,	mostly	for	the	customers	and	the	patients.	
In	the	future,	the	evaluations	will	be	extended	and	the	potential	advantages,	
disadvantages	and	cost	effects	will	be	analysed	more	profoundly	and	from	
other	angles.	As	far	as	possible,	the	evaluation	tools	will	be	evidence-based	
meters.
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6.2 TIMETABLE
The	preparations	for	the	Medicines	Policy	2020	started	in	January	2010.	
The	development	of	the	practical	actions	under	the	medicines	policy	out-
lines	as	well	as	the	impact	indicators	started	in	late	2010.	At	this	stage,	two	
benchmark	points	for	the	revision	of	the	actions	will	be	set.	The	first	one	
is	the	meeting	of	the	Medicines	Group,	constituted	by	the	pharmaceutical	
sector	authorities,	in	the	autumn	of	2011.	At	this	venue,	the	medicines	po-
licy	objectives	and	actions	will	be	revised	as	per	the	publication	of	the	new	
Government	programme.	
The	Pharmaceutical	Forum	constituted	by	the	stakeholders	is	the	second	
benchmark	point.	The	Forum	will	be	convened	in	2012,	and	it	will	analyse	the	
implementation	and	measuring	of	the	medicines	policy	from	the	perspective	
of	the	stakeholders.	The	Medicines	Group	will	also	convene	in	2012,	and	the	
future	benchmark	points	and	practical	actions	will	be	agreed	upon	in	these	
meetings.
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APPENDIX 1
Healthcare expenditure in 1995-2008 at 2008 prices, in millions euro 
Gross investments in healthcare
Travelling  
Administrative expenses of 
healthcare  
Equipment and other medicinal 
durables  
 
Medicines and other medicinal 
consumables  
 
Other healthcare  
Private healthcare (reimbursed 
from health insurance)
 
 
Inpatient care of older persons
 Occupational and student 
healthcare  
Dental healthcare  
Primary healthcare (excluding 
occupational, student and dental 
healthcare)
Specialised medical care
Source: National Institute for Health and Welfare 2010 
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APPENDIX 3
Organisations involved in the preparation of the Medicines Policy 2020
Ministry	of	Social	Affairs	and	Health	Finnish	Medicines	Agency	Fimea
National	Supervisory	Authority	for	Welfare	and	Health	Valvira
Social	 Insurance	 Institution	 Ministry	 of	 Social	 Affairs	 and	 Health/
Pharmaceuticals	Pricing	Board	
Ministry	of	Social	Affairs	and	Health/Insurance	Department
Ministry	of	Agriculture	and	Forestry	Finnish	Food	Safety	Authority	Evira
Hospital	pharmacies
Hospital	districts
Co-operation	organisation	of	the	social	welfare	and	health	organisations	YTY
Association	of	Finnish	Pharmacies
The	Finnish	Pharmacists'	Association	
Suomen	Proviisoriyhdistys	(Finnish	Association	of	Senior	Pharmacists)
Association	of	Finnish	Local	and	Regional	Authorities
Finnish	Medical	Association
Finnish	Dental	Association
Finnish	Veterinary	Association
The	Finnish	Union	of	Practical	Nurses	SuPer
Union	of	Health	and	Social	Care	Professionals	Tehy
Pharmacy	wholesalers
University	of	Helsinki
University	of	Eastern	Finland
University	of	Turku
University	of	Tampere
Åbo	Akademi	University
Pharma	Industry	Finland	PIF
Finnish	Generic	Pharmaceutical	Industry	
Federation	of	Finnish	Patients
Finnish	Medical	Society	Duodecim
Helsinki	University	Pharmacy
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APPENDIX 4
Abbreviations used in the Medicines Policy 2020 document
Abbreviation  Definition
EU		 	 European	Union
Evira		 	 Finnish	Food	Safety	Authority	
Fimea		 	 Finnish	Medicines	Agency	
CMR		 	 comprehensive	medication	review	
Rohto	 	 Centre	for	Pharmacotherapy	Development	Rohto
SFL		 	 Finnish	Pharmacy	Federation
SITRA			 Finnish	Innovation	Fund	SITRA
Stakes	 	 National	Research	and	Development	Centre	for	Welfare	and	
	 	 	 Health
TEKES		 Finnish	Funding	Agency	for	Technology	and	Innovation
TUKIJA	 	National	Committee	on	Medical	Research	Ethics	
Valvira			 National	Supervisory	Authority	for	Welfare	and	Health
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APPENDIX 5
Definitions used in the Medicines Policy 2020 document 
1) Pharmaceutical service (Pharmaceutical sector) 
Pharmaceutical service
A	whole	to	ensure	the	availability	of	efficient,	safe	and	reasonably	priced	
medicines.	The	elements	included	are	pharmaceutical	development	and	
production,	imports,	wholesale	and	retail	distribution	of	pharmaceuticals,	
prescription	of	medicines,	research	on	the	use	of	medicines	and	pharmaceutical	
service	research,	medicines	reimbursement	system,	pharmaceutical	service	
administration,	obligatory	stockpiling	and	security	of	supply.	Pharmaceutical	
service	comprises	both	outpatient/non-institutional	and	inpatient	care.	
2) Patient safety, medicine/drug safety and medication safety 
Patient safety
Principles	and	actions	of	the	healthcare	units	and	organisations,	with	the	
purpose	of	ensuring	the	safety	of	the	care	and	protect	the	patient	from	any	
harm;	from	the	patient’s	point	of	view:	that	the	care	does	not	cause	any	
significant	adverse	effect;	comprises	both	the	safety	of	the	care,	medication	
safety	and	safety	of	the	devices	as	a	part	of	the	care	quality	(Source:	National	
Research	and	Development	Centre	for	Welfare	and	Health	Stakes	and	Centre	
for	Pharmaceutical	Development	Rohto,	2006	
Safe medication 
Safe	medication	 comprises	 drug	 safety	 and	medication	 safety	 (Fimea	
administrative	regulation	7/2007,	Stakes	and	Rohto	2006).	
Drug/medicine safety 
The	term	mostly	comprises	the	safety	of	the	medicine	seen	as	a	product:	the	
knowledge	and	evaluation	of	the	medicine's	pharmacological	properties	and	
effects,	its	high-quality	manufacturing	process	as	well	as	the	information	
on	the	package	and	other	product	information.	The	efficacy	and	safety	of	
medicines	is	evaluated	through	the	marketing	authorisation	procedure.	The	
concern	for	adverse	reactions	(ADR)	also	continues	after	the	marketing	
authorisation	has	been	granted	(so-called	subsequent	supervision,	in	other	
words	pharmacovigilance)	(Source:	Stakes	and	Rohto	2006).	
Medication safety 
The	safety	in	relation	to	the	use	of	medicines.	The	term	covers	the	principles	
and	operations	of	the	social	welfare	and	healthcare	units,	geared	at	ensuring	
the	safety	of	pharmacotherapies	and	protecting	the	patient	from	harm.	
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Medication	safety	comprises	actions	to	prevent,	avoid	and	rectify	adverse	
events	related	to	the	use	of	medicines	(Source:	Stakes	and	Rohto	2006).	
User safety 
Prevention	of	harm	caused	to	humans	by	handling	or	dosage	of	veterinary	
medicines.	
3) Rational pharmacotherapy, monitoring of drug treatment, comprehensive 
medication review CMR as well as rational self-medication 
Rational pharmacotherapy 
Rational	pharmacotherapy	is	efficient,	safe,	cost-effective	and	purposeful	
pharmacotherapy	(WHO).	
Monitoring of drug treatment 
Part	of	the	medication	process,	see	medication	process.	
Drug utilisation/regimen review/Medication review
Review	of	an	individual	patient’s	medication	by	a	health	care	professional	
(physician,	nurse,	senior	pharmacist,	pharmacist)	checking	the	medicine	
dosage	and	administration	times	against	the	approved	clinical	practice,	
detecting	eventual	overlapping	or	incompatible	medications.	Performed	as	
an	element	of	normal	doctor’s	appointment,	dispensing	of	the	medicine	at	the	
pharmacy	or	distribution	at	a	hospital	ward	or	in	home	care.	The	pharmacy	
also	makes	reviews	for	self-care	medicines.	Does	not	include	the	evaluation	
of	medication	need	or	indication	(Adapted	from	Peura	et	al	2007).	
Medication assessment/review 
As	a	part	of	the	normal	patient	examination	and	treatment	planning	process,	
a	review	of	an	individual	patient’s	medication,	its	need	and	rationality,	made	
by	a	physician	and	assisted	by	other	healthcare	professionals,	if	necessary.	
Comprehensive medication assessment, comprehensive medication review 
(CMR), medication therapy management service 
The	solution	of	an	individual	patient’s	medication	problems,	initiated	by	
the	attending	physician	in	collaboration	with	clinical	experts	and/or	an	
interprofessional	group.	In	addition	to	the	assessment	by	the	attending	
physician,	CMR	can	include	a	thorough	analysis	of	the	medication	whole	
and	proposed	actions,	performed	by	a	clinical	pharmacologist,	specially	
trained	senior	pharmacist	or	pharmacist	or	other	specially	trained	healthcare	
professional	(Adapted	from	Peura	et	al.	2007).	
Self-medication	
Self-medication	based	on	self-care	medicines	(see	also	item	5).	
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4) Integrated care pathway, individual treatment pathway, pharmacotherapy 
process, unit-based and individual pharmacotherapy plan, interprofessional 
collaboration and ward pharmacy 
[Disease based] integrated care pathway, pathway of care, clinical pathway, 
seamless care
Organisation-oriented,	planned	and	individually	implemented,	regionally	
agreed	whole	of	treatment	processed	targeted	at	the	same	client/patient	
and	 their	particular	 symptoms.	Based	on	 the	agreements	between	 the	
organisations	on	the	arrangement	of	the	treatment	of	a	particular	disease	
(Source:	Norback	et	al.	2010)	
Individual treatment pathway 
The	individual	treatment	pathways	(also	 'care	pathway’)	refer	to	 inter-
organisational	planned	and	individually	implemented	whole	of	treatment	
processes	targeted	at	the	same	client’s	particular	symptoms.	The	individual	
treatment	pathways	require	that	one	unit	is	responsible	for	the	guidance	
and	monitoring	of	the	services	provided	to	the	client	(Source:	Norback	et	
al.	2010).	
Pharmacotherapy process 
A	patient’s	pharmacotherapy	process	is	an	operative	chain	comprising	the	
assessment	of	medication	need,	the	choice	and	dispensing	of	the	medicine,	its	
dosage	and	administration,	the	patient’s	motivation,	advice	and	commitment	
to	the	pharmacotherapy,	organisation	of	the	treatment	follow-up	and	the	
evaluation	of	the	outcome,	as	well	as	ensuring	the	informing	of	the	patient	
and	the	organisations	and	persons	involved	in	the	treatment.	A	patient-specific	
pharmacotherapy	plan	is	part	of	the	pharmacotherapy	process.	
Unit-based pharmacotherapy plan, unit-based medicines management plan 
Performed	in	line	with	the	instructions	issued	by	the	Ministry	of	Social	
Affairs	and	Health,	a	plan	on	the	implementation	of	pharmacotherapies	in	
public	and	private	social	welfare	and	healthcare	units.	The	management	of	
the	social	welfare	or	healthcare	unit	is	in	charge	of	organising	the	drafting,	
implementation	and	follow-up	of	the	pharmacotherapy	plan.	The	hospital	
pharmacy	or	medicine	dispensary	responsible	for	the	pharmaceutical	service	
in	the	unit	will	participate	in	the	drafting	of	the	pharmacotherapy	plan	(STM	
2006,	Fimea	administrative	regulation	7/2007).	
Individual pharmacotherapy plan 
Part	of	a	patient’s	treatment	plan.	Regularly	updated	and	included	in	the	
patient	records,	a	summary	on	the	medicines	used	by	the	patient,	their	
indications,	treatment	objectives,	medicine	dosage	as	well	as	treatment	
follow-up	 and	duration.	This	 plan	 constitutes	 the	 basis	 for	 individual	
pharmacotherapy,	decreasing	the	erroneous	use	of	medicines.	
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Interprofessional collaboration 
In	interprofessional	collaboration,	various	professional	groups	coordinate	their	
action	in	the	best	interest	of	the	patient,	also	understanding	the	tasks	and	
responsibilities	of	other	professional	groups	in	the	treatment	of	the	patient	as	
well	as	the	importance	of	exchange	of	information	between	the	professional	
groups	(Source:	Zwarenstein	et	al.	2009).	
Ward pharmacy 
Ward	pharmacy	 is	 the	pharmaceutical	 service	work	performed	by	 the	
pharmaceutical	staff	at	the	wards	(Fimea	administrative	regulation	7/2007).	
5) Customer-orientation, treatment adherence, concordance, self-
management, self-care
Customer oriented services, patient oriented services
The	organisation’s	approach	 in	 the	planning	and	 implementation	of	 its	
operations	from	the	customer/patient	perspective.	
Compliance 
The	patient	follows	the	medical	instructions	without	necessarily	having	a	
deeper	insight	of	them	(WHO	2003).	In	veterinary	medicine,	this	means	
that	the	medication	administered	by	the	owner	takes	place	according	to	the	
veterinarian's	instructions.	
Adherence 
Responsible	and	active	self-care	by	the	patient,	in	a	way	complying	with	the	
state	of	health	and	in	collaboration	with	the	healthcare	professionals	(Kyngäs	
1995).	
Concordance 
Joint	understanding	on	the	treatment	as	a	result	of	a	negotiation	between	the	
patient	and	the	healthcare	professional.	In	order	to	improve	the	conditions	for	
rational	pharmacotherapy,	the	negotiation	also	addresses	the	patient's	wishes,	
beliefs	and	underlying	knowledge.	
Self-management 
An	operational	model	promoting	adherence	to	treatment	where	the	patient	is	
directed	to	take	individual	responsibility	for	their	care.	This	includes	actions	
to	maintain	and	promote	health	and	follow-up	and	treatment	of	the	symptoms	
of	the	disease,	geared	to	manage	the	impact	of	the	disease	on	the	patient’s	
operating	capacity,	emotions	and	social	life.	
Self-care 
The	individual’s	voluntary	operation	targeted	at	maintained	health.	Rational	
use	of	self-care	medicines	is	part	of	self-care.	In	animals,	the	veterinary	self-
care	medicines	are	used	rationally	and	with	caution	to	maintain	their	health.	
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6) Efficacy, effectiveness, cost-effectiveness (efficiency) and incremental cost-
effectiveness ratio (ICER) 
Efficacy 
The	effect	of	the	treatment	under	ideal	circumstances,	observed	in	closely	
monitored	test	conditions	on	selected	patients.	The	proof	of	efficacy	is	one	
of	the	preconditions	for	the	granting	of	the	marketing	authorisation	for	a	
medicinal	product.	Reply	to	the	question:	can	the	treatment	work?	
Effectiveness 
The	impact	of	the	treatment	obtained	at	the	population	level,	in	normal	
conditions	and	on	unselected	group	of	patients.	Reply	to	the	question:	will	
the	treatment	work	in	practice?	
Cost-effectiveness (= efficiency) 
The	relation	between	the	effectiveness	of	the	treatment	and	the	resources	
(costs)	incurred	for	administering	it.	Reply	to	the	question:	is	the	treatment	
economically	feasible?	
Incremental cost-effectiveness ratio ICER 
ICER	shows	how	many	more	monetary	units	must	be	paid	for	each	extra	
unit	of	benefits	(such	as	avoided	harm,	additional	life	year,	quality-adjusted	
life	year	QALY.	Sources:	Gold	et	al.	1996,	Drummond	et	al.	2005,	Sintonen	
and	Pekurinen	2006,	Mäkelä	et	al.	2007).	
7) Pharmaceutical research 
At	all	levels	and	areas	of	pharmaceutical	or	veterinary	pharmaceutical	service,	
operations	targeted	at	the	development	of	medicines	and	the	investigation	of	
their	properties	or	impacts,	the	advantages	gained	or	adverse	effects	caused	
by	them.	
Clinical research
Experimental	research	and	trials	on	humans,	mostly	targeted	at	demonstrating	
the	efficacy	and	safety	of	a	medicine	or	other	form	of	therapy.	
Basic research
Research	comprises	basic	research	and	applied	research.	The	main	purpose	
of	basic	research	is	to	increment	general	knowledge,	thereby	understanding	
the	links	between	various	variables.	
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8) Pharmaceutical information 
Pharmaceutical (drug/medicines) information 
Information	about	medicines	and	pharmacotherapies,	available	to	consumers	
and	healthcare	professionals	through	various	information	channels,	either	face-
to-face	or	through	written	or	electronic	services	(telephone,	Internet,	TV	and	
radio).	Pharmaceutical	information	is	produced	by	the	authorities,	healthcare	
professionals,	the	pharmaceutical	industry	and	patient	organisations.	The	basis	
of	medicine-specific	information	is	the	summary	of	product	characteristics,	
SPC)	adopted	together	with	the	marketing	authorisation,	as	well	as	the	
package	leaflet	based	on	it.	(Sources:	Directive	2001/83/EC,	Pohjanoksa-
Mäntylä	2010,	Salonen	2010).
Patient/medication counselling 
A	discussion	between	the	client/patient	and	the	healthcare	professional	
where	the	professional,	taking	the	client’s	personal	needs	and	situation	into	
consideration,	supports	his	or	her	coping	with	the	pharmacotherapy	(Sources:	
USP	1997,	Hakkarainen	and	Airaksinen	2001)	
9) Veterinary service
Animal	healthcare	and	treatment	of	animal	diseases	as	well	as	other	veterinary	
assistance,	meat	and	milk	inspection,	health-related	control	and	inspection	
of	the	production	of	animal-based	foodstuffs	and	animal	husbandry,	fighting	
and	prevention	of	veterinary	diseases	as	well	as	animal	protection	(Veterinary	
Service	Act	685/1990).	
